Ascletis Pharmaceuticals Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ASC40
Drug: rifampicin
Drug: Itraconazole
First Posted Date
2021-04-13
Last Posted Date
2021-08-23
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
24
Registration Number
NCT04843449
Locations
🇨🇳

Hunan provincial people's hospital, Changsha, Hunan, China

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ASC09F
First Posted Date
2020-09-14
Last Posted Date
2021-01-11
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
12
Registration Number
NCT04547894
Locations
🇨🇳

Beijing Youan Hospital, Capital Medical University, Beijing, Beijing, China

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ASC41
Drug: ASC41 placebo
First Posted Date
2020-08-26
Last Posted Date
2021-08-20
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
60
Registration Number
NCT04527250
Locations
🇨🇳

Hunan provincial people's hospital, Changsha, Hunan, China

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Phase 2
Completed
Conditions
Chronic Hepatitis b
Interventions
Drug: ASC22
Drug: sodium chloride
First Posted Date
2020-07-10
Last Posted Date
2024-12-02
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
207
Registration Number
NCT04465890
Locations
🇨🇳

Peking University First Hospital, Beijing, China

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ravidasvir and sofosbuvir
Drug: ASC18
First Posted Date
2020-04-24
Last Posted Date
2021-01-11
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
50
Registration Number
NCT04358523
Locations
🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: TVB-2640
Drug: Placebo
First Posted Date
2020-04-20
Last Posted Date
2020-07-07
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
34
Registration Number
NCT04352361
Locations
🇨🇳

Hunan provincial people's hospital, Changsha, Hunan, China

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

First Posted Date
2018-02-13
Last Posted Date
2018-06-29
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
12
Registration Number
NCT03430830
Locations
🇨🇳

First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

First Posted Date
2017-12-05
Last Posted Date
2020-07-28
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
425
Registration Number
NCT03362814
Locations
🇨🇳

Peking University People's hospital, Beijing, Beijing, China

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

First Posted Date
2017-09-20
Last Posted Date
2018-01-17
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
18
Registration Number
NCT03288636
Locations
🇨🇳

The first hospital of Zhejiang province, Hangzhou, Zhejiang, China

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

First Posted Date
2017-01-13
Last Posted Date
2021-03-23
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
141
Registration Number
NCT03020082
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy